Safety of intravenous iron use in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 6, 2016, Pages 529-535

  Kalra, Philip A ^a   Bhandari, Sunil ^b  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

anaphylaxis risk; chronic kidney disease; intravenous iron; iron deficiency anaemia

Indexed keywords

IRON; IRON DEXTRAN;

ANAPHYLAXIS; CARDIOVASCULAR DISEASE; CELL DAMAGE; CHRONIC KIDNEY DISEASE; DRUG SAFETY; ESOPHAGITIS; HUMAN; HYPERSENSITIVITY; HYPOPHOSPHATEMIA; INFECTION; INFECTION RISK; IRON DEFICIENCY ANEMIA; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; CHRONIC KIDNEY FAILURE; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; HUMANS; IRON; RENAL INSUFFICIENCY, CHRONIC;

EID: 84983311761     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000263     Document Type: Review

References (47)

1. Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care 2009; 32:1320-1326.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
3. Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol 2012; 3:177-191.
4. Henry DH. The role of intravenous iron in cancer-related anemia. Oncology (Williston Park) 2006; 20 (8 Suppl 6):21-24.
5. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9:211-222.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., Suppl. 2012; 2:279-335.
7. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13:1545-1553.
8. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134:1318-1328.
9. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran: A comparison of two products. Am J Nephrol 2000; 20:455-462.
10. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37:743-749.
11. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19:1571-1575.
12. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378-382.
13. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41 (5 Suppl): 18-26.
14. Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 36:88-97.
15. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314:2062-2068.
16. DeLoughery TG, Auerbach M. Is low-molecular weight iron dextran really the most risky iron?. Unconvincing data from an unconvincing study. AmJ Hematol 2016; 91:451-452.
17. Auerbach M, Ballard H, Glaspy J. Clinical update: Intravenous iron for anaemia. Lancet 2007; 369:1502-1504.
18. Del VL, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J 2016; 9:260-267.
19. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management. Haematologica 2014; 99:1671-1676.
20. Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: Classification, terminology, mechanisms and management. Br J Pharmacol 2015; 172:5025-5036.
21. Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: Conclusions from a 'Kidney Disease: Improving Global Outcomes' (KDIGO) Controversies Conference. Kidney Int 2016; 89:28-39.
22. http://www.meddra.org/standardised-meddra-queries. [Accessed 6 June 2016].
23. CDER Medical Review of Ferric carboxymaltose, Application Number: 203565Orig1s000. 21-7-2013. [Accessed 6 June 2016].
24. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis 1999; 34 (4 Suppl 2):S47-S52.
25. Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014; 29:809-822.
26. Fell LH, Seiler-Mussler S, Sellier AB, et al. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. Nephrol Dial Transplant 2016; doi: 10.1093/ndt/gfw045, [Epub ahead of print]
27. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother 2007; 41:1476-1480.
28. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88:905-914.
29. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347:f4822.
30. Munoz M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347:f4822 (response). [Accessed 6 June 2016].
31. Anker SD, Comin CJ, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436-2448.
32. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29:2075-2084.
33. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002; 57:457-461.
34. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc 2015; 90:12-23.
35. Ishida JH, Marafino BJ, McCulloch CE, et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clin J Am Soc Nephrol 2015; 10:1799-1805.
36. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40:90-103.
37. Bresgen N, Eckl PM. Oxidative stress and the homeodynamics of iron metabolism. Biomolecules 2015; 5:808-847.
38. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65:2279-2289.
39. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney Int 2004; 66:144-156.
40. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in nondialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2015; 31:646-655.
41. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis 2016; 9:53-64.
42. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion 2009; 49:2719-2728.
43. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28:1793-1803.
44. Dahlerup J, Jacobsen BA, van der Woude J, et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol 2016; 21:1-7.
45. Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant 2015; 30:1577-1589.
46. Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78:480-491.
47. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: Facts and folklore. Blood Transfus 2014; 12:296-300.